Todd C. Brady
President and CEO at Aldeyra Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Aldeyra Therapeutics Inc., 3 years.
Aldeyra Therapeutics Inc.
Director · President and CEO
Chief executive roles
Aldeyra Therapeutics Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 3, 2026 | Aldeyra Therapeutics Inc. | Open-market purchase | +250,000 | $1.67 | $417,500 |
| Mar 12, 2024 | Aldeyra Therapeutics Inc. | Open-market sale | −85,324 | $3.05 | $260,238 |
| Mar 11, 2024 | Aldeyra Therapeutics Inc. | Open-market sale | −97,914 | $3.27 | $320,179 |
| Sep 7, 2023 | Aldeyra Therapeutics Inc. | Option exercise | +192,084 | $0.55 | $105,646 |
| Sep 7, 2023 | Aldeyra Therapeutics Inc. | Option exercise | +32,953 | $0.55 | $18,124 |
| Sep 7, 2023 | Aldeyra Therapeutics Inc. | Option exercise | +48,021 | $0.55 | $26,412 |
| Sep 7, 2023 | Aldeyra Therapeutics Inc. | Shares withheld for tax | −73,807 | $7.22 | $532,887 |
| Feb 28, 2023 | Aldeyra Therapeutics Inc. | Grant or award | +238,750 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.